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Abstract Molecular subtyping of breast cancer may
provide additional prognostic information regarding patient
outcome. However, its clinical significance remains to be
established. In this study, the main aims were to discover
whether reclassification of breast cancer into molecular
subtypes provides more precise information regarding
outcome compared to conventional histopathological
grading and to study breast cancer-specific survival in the
different molecular subtypes. Cases of breast cancer
occurring in a cohort of women born between 1886 and
1928 with long-term follow-up were included in the study.
Tissue microarrays were constructed from archival for-
malin-fixed, paraffin-embedded tissue from 909 cases.
Using immunohistochemistry and in situ hybridisation as
surrogates for gene expression analyses, all cases were
reclassified into the following molecular subtypes: Luminal
A; Luminal B (HER2-); Luminal B (HER2?); HER2
subtype; Basal phenotype; and five negative phenotype.
Kaplan–Meier survival curves and Cox proportional haz-
ards models were used in the analyses. During the first
5 years after diagnosis, there were significant differences in
prognosis according to molecular subtypes with the best
survival for the Luminal A subtype and the worst for HER2
and five negative phenotype. In this historic cohort of
women with breast cancer, differences in breast cancer-
specific survival according to subtype occur almost
exclusively amongst the histopathological grade 2 tumours.
From 5 years after time of diagnosis until the end of fol-
low-up, there appears to be no difference in survival
according to molecular subtype or histopathological grade.
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Abbreviations
BCSS Breast cancer-specific survival
BP Basal phenotype
CI Confidence intervals
CISH Chromogenic in situ hybridization
CK5 Cytokeratin 5
EGFR Epithelial growth factor receptor 1
ER Oestrogen receptor
FFPE Formalin-fixed, paraffin-embedded
GGI Gene expression grade index
HER2 Human epidermal growth factor receptor 2
HES Haematoxylin–erythrosin–saffron
HR Hazard ratio
IHC Immunohistochemistry/immunohistochemical
PR Progesterone receptor
5NP Five negative phenotype
SI Staining index
TMA Tissue microarray
Introduction
Breast cancer is the most common cancer and leading
cause of cancer-related death amongst women worldwide
[13, 35]. The disease is heterogeneous in its histopathol-
ogy, therapeutic response, metastatic patterns and outcome.
Current treatment guidelines are based on histopathological
grading, tumour size, lymph node-, hormone receptor-,
human epidermal growth factor receptor 2 (HER2)- and
proliferation (Ki67) status. More recently, gene expression
analyses using c-DNA microarray technology have pro-
vided a deeper understanding of the complexity of breast
cancer. Perou et al. [30] describe four molecular subtypes:
Luminal-like, HER2 enriched, Basal-like and Normal-like.
More recent publications have confirmed these subtypes
with some modifications and it has been shown that
molecular subtypes also differ in their response to treat-
ment and outcome [4, 8]. Molecular subtyping with
immunohistochemistry (IHC) and in situ hybridisation
(ISH) as surrogates for gene expression analyses makes it
possible to study large numbers of archival breast cancer
cases with long-term follow-up.
Histopathological grade is a well-established prognostic
factor [3, 12, 32]. Recent studies confirm the importance of
grading in breast cancer prognostication, although grading
systems based on gene expression, such as the Gene
expression grade index (GGI), have recently emerged [7,
32, 37]. Molecular subtyping may provide additional
information on patient outcome, but consensus has yet to
be reached regarding IHC or ISH markers that could be
used as surrogates for gene expression analyses [17]. Most
surrogate markers used for subtyping are available in
clinical practice today, but it remains to document the
benefits of a new classification prior to implementation.
The aims of this study were to discover whether
reclassification of breast tumours into molecular subtypes
provides more information regarding outcome compared to
conventional histopathological grading and to study breast
cancer-specific survival (BCSS) for molecular subtypes
over time. To achieve this, a cohort of breast cancer cases
with long-term follow-up was reclassified into molecular
subtypes. Most of the markers examined are widely used,
such as oestrogen receptor (ER), progesterone receptor
(PR), HER2 and Ki67. In addition, cytokeratin 5 (CK5) and
epithelial growth factor receptor 1 (EGFR) were included
[2, 6]. The patients in this population experienced breast
cancer in a time period or at an age where adjuvant treat-
ment after surgery was rarely an option and the disease thus
had a near-natural course.
Materials and methods
Study population
Between 1956 and 1959, 25,897 women in the Norwegian
county of Nord-Trøndelag, born between 1886 and 1928,
were invited to participate in a screening programme for
early diagnosis of breast cancer [22, 29]. The screening
comprised a clinical examination and a questionnaire
focussed on reproductive history. Data were linked with the
Norwegian Cancer Registry and the Cause of Death Reg-
istry of Norway. In all, 1,393 new cases of breast cancer
occurred between 1961 and 2008. Most of these were
analysed at the Department of Pathology, St. Olav’s Hos-
pital, Trondheim University Hospital, Norway. A total of
448 cases were excluded from the study. For the remaining
945 cases, formalin-fixed, paraffin-embedded (FFPE) tis-
sue was available and 909 were of sufficient quality for
reclassification into molecular subtypes (see Fig. 1).
Specimen characteristics
Pathology reports and FFPE tissue from all cases were
retrieved from the archives of the department of pathology.
In cases with recurrent disease or second or multiple pri-
mary breast cancer, only the first primary tumour was
included. New 4-lm-thick full-face sections were cut from
representative paraffin blocks from tumours and lymph
node metastases and stained with haematoxylin–erythro-
sine–saffron (HES). Forty cases comprised only core
biopsies or small tissue fragments unsuitable for tissue
microarray (TMA). From these, serial sections were made.
The HES-stained sections were reviewed under a
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microscope independently by two experienced pathologists
(OAH, AMB) and classified according to histopathological
type and grade according to the World Health Organization
Classification of Tumours [23] and the Nottingham grading
system [12, 33]. Any discrepancies in grade or type were
discussed and consensus reached. In cases where tumour
size was missing in the pathology report, size was mea-
sured in millimetres on the glass slide. Only cases with a
measurement of the whole tumour in the pathology report
and/or measurement of the full diameter on the glass slide
were registered. All other cases were classified as size
uncertain [n = 268 (29.5 %)].
TMA construction
TMA blocks were made using the Tissue Arrayer Mini-
Core 3 with TMA Designer2 software (Alphelys). Areas
of interest in the HES sections were marked by a pathol-
ogist. Three 1-mm-diameter tissue cores were extracted
from peripheral regions of the tumour in the FFPE blocks
and inserted into TMA recipient blocks. From the TMA
blocks, 4-lm sections were cut and stained. IHC was done
with antibodies for ER, PR, HER2(CB11), CK5, Ki67 and
EGFR in addition to HES staining. In addition, HER2
status was also examined by chromogenic in situ hybrid-
ization (CISH).
Assay methods
Sections were mounted on Superfrost?glass slides, dried at
37 C overnight and stored at -20 C. All sections were
stained within 12 weeks of sectioning. The slides were
heated to 60 C for 2 h. Pre-treatment was performed in a PT
Link, Pre-Treatment Module for Tissue Specimens (Dako)
with buffer (High pH Target Retrieval Solution K8004) at
97 C for 20 min. All sections were immunostained for ER,
PR, HER2 (CB11), CK5 and Ki67 in a DakoCytomation
Autostainer Plus (Dako). For visualization, the Dako
REALTM EnVisionTM Detection System was used with
Peroxidase/DAB?, Rabbit/Mouse, code K5007. EGFR was
immunostained using EGFR pharmDxTM for autostainer,
code K1494. See Table 1 for sources and dilutions of pri-
mary antibodies. Negative controls were included in each
staining run. CISH was used to visualize the HER2 gene (red
chromagen) and chromosome 17 (blue chromagen) using the
dual colour probe kit HER2 CISH pharmDxTM Kit, code 109
(Dako). Two of the steps in the CISH procedure were mod-
ified slightly. The incubation time for red chromogen solu-
tion was increased from 10 to 15 min, and the dilution of
haematoxylin was increased from 1:5 to 1:7.
Scoring and reporting
All HES- and IHC-stained slides were digitalized using the
tissue scanner AriolTM SL-50 3.3 Scan system and analysis
station (Genetix) at 59 and 209 magnification. Expression
of ER, PR, HER2 (CB11), CK5, Ki67 and EGFR was
evaluated using the Ariol review station. The images were
viewed and subjectively scored by two persons indepen-
dently. HER2 gene amplification status was annotated
under a bright field microscope. All cases were evaluated
by at least one pathologist. Any discrepancies were dis-
cussed and consensus reached.
Classification of each marker
ER and PR were positive when C1 % of the tumour cells
showed positive nuclear staining [19]. For Ki67, a total of
500 tumour nuclei were examined. Cases with C15 %
positive nuclei were classified as Ki67 high and \15 % as
Ki67 low [16].
HER2 was assessed using both IHC and CISH [11]. For
HER2 IHC, the CB11 clone [31, 43] was used and the
Herceptest (Dako) guidelines for interpretation were used
with a membrane-staining score ranging from 0 to ?3.
Fig. 1 Study population
Table 1 Sources and dilutions of primary antibodies
Antibody Clone Manufacturer Concentration
of antibody
Dilution
ER SP1 Cell marque 33 mg/ml 1:100
PR 16 Novocastra 360 mg/l 1:400
HER2 CB11 Novocastra 3.9 g/l 1:640
Ki67 MIB1 Dako 35 mg/l 1:100
CK5 XM26 Novocastra 50 mg/l 1:100
EGFR 2-18C9 Dako Ready to use No dilution
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HER2 IHC was considered negative when the score was 0
or ?1, positive when ?3 and borderline when ?2. Since
the preanalytical treatment of the samples was unknown,
the results of HER2 IHC were only used in cases where
CISH was unsuccessful. In IHC (?2) and unsuccessful
CISH (18 cases), the corresponding IHC was revised by
two authors (AMB and MJE) and reclassified as either
?1(14 cases) or ?3(4 cases).
The HER2 gene was considered amplified if the gene to
chromosome ratio was C2.0 [1, 34]. A minimum of 20
non-overlapping nuclei with signals for both chromosome
and gene were assessed.
For CK5, a staining index (SI) was estimated. Staining
intensity was graded as 0 (no staining), 1 (weak), 2
(moderate) and 3 (strong). The proportion of positive
staining cells was scored as 1 (\10 %), 2 (10–50 %) and 3
([50 %). The score for intensity multiplied by proportion
is the SI [14, 26]. In this study, the results were considered
to be negative when SI was 0–1 and positive when the SI
was 2–9. For EGFR, membranous staining was scored
according to the guidelines in the Dako PharmDx kit and a
SI was calculated when this was combined with the pro-
portion of cells showing positive staining resulting in a SI
as described above.
Classification of molecular subtypes
Using the six biomarkers, the tumours were then classified
in molecular subtypes: Luminal A, Luminal B (HER2-),
Luminal B (HER2?), HER2 subtype five negative phe-
notype (5NP) and Basal-like phenotype (BP) (Fig. 2).
Statistical analyses
All women were followed from the date of breast cancer
diagnosis to the date of death from breast cancer, death
from any other cause or to the end of follow-up (December
31, 2010), whichever came first. BCSS according to
molecular subtypes and histopathological grade was esti-
mated using Kaplan–Meier methods and compared by log-
rank tests. Cox proportional hazards models were used to
estimate risk of death from breast cancer adjusted for age
(5-year intervals), stage (in five categories: stage I–IV and
unknown) at diagnosis according the data from the Cancer
Registry [21] and time period of diagnosis (10-year inter-
vals). Hazard ratios (HR) were calculated with 95 % con-
fidence intervals (CI) for two time periods: first 5 years
after diagnosis and from 5 years after diagnosis and
onwards (conditional on surviving the first 5 years). Cox
analyses of the first 5 years were stratified by histopa-
thological grade. Statistical analyses were carried out using
Stata version 12.1 IC for Windows (Stata Corp.). This
study complies with the REMARK reporting recommen-
dations for tumour marker studies [25].
Ethics
The study was approved by the Regional Committee for
Medical and Health Sciences Research Ethics (REK, Midt-
Norge, ref. nr: 836/2009) and dispensation from the
requirement of patient consent was granted.
Results
Description of the population
In all, 909 cases were included. Mean age at diagnosis was
72.5 years (SD 10.7; range 41–102). Only 12.5 %
were \60 years and 58.9 % were 60–79 years. Most
tumours were 2–5 cm in diameter (43.2 %), but for
29.5 %, tumour size was unknown or uncertain. At the end
of the observation period, 359 (39.5 %) had died of breast
cancer, 390 (42.9 %) of other causes and 160 (17.6 %)
Fig. 2 Classification algorithm
for molecular subtyping
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were still alive. Median follow-up was 6.4 years [inter-
quartile range (IQR) 10.0 years]. See Table 2 for patient
and tumour data.
Histopathological characteristics
Of the 909 tumours, 12.9 % were grade 1, 53.7 % grade 2
and 33.4 % grade 3. The histopathological types were as
follows: ductal: 70.0 %; lobular: 13.6 %; and other special
types: 16.4 %. All cases were reclassified into molecular
subtypes based on assessment of ER, PR, HER2, Ki67, CK5
and EGFR. Table 2 shows distribution of histopathological
types and grades for each molecular subtype. Table 3 shows
the number of positive cases of each marker.
Distribution of molecular subtypes
The distribution of subtypes was as follows: Luminal A:
47.6 %; Luminal B (HER2-): 27.4 %; Luminal B
(HER2?): 7.7 %; HER2 subtype: 6.6 %; 5NP: 3.6 %; and
Table 2 Descriptive statistics for the 909 breast cancer cases
Luminal
A
Luminal B
(HER2-)
Luminal B
(HER2?)
HER2
type
5 Negative
phenotype
Basal
phenotype
Total
Number (%) 433 (47.6) 249 (27.4) 70 (7.7) 60 (6.6) 33 (3.6) 64 (7) 909
Mean age at diagnosis (SD) 73.9 (9.9) 71.9 (10.9) 69 (11.4) 67.3 (11.6) 75.9 (11.1) 71.7 (11.3) 72.5 (10.7)
Median years of follow-up after
diagnosis (IQR)
7.4 (9.3) 7.0 (11.1) 5.2 (12.5) 3.2 (8.1) 3.4 (8.5) 5.1 (9.1) 6.4 (10.0)
Tumour grade (%)
1 91 (21.0) 20 (8.0) 2 (2.9) 0 0 4 (6.3) 117 (12.9)
2 297 (68.6) 120 (48.2) 33 (47.1) 10 (16.7) 21 (63.6) 7 (10.9) 488 (53.7)
3 45 (10.4) 109 (43.8) 35 (50.0) 50 (83.3) 12 (36.4) 53 (82.8) 304 (33.4)
Histopathological type (%)
Ductal 299 (69.1) 182 (73.1) 57 (81.4) 47 (78.3) 14 (42.4) 37 (57.8) 636 (70.0)
Lobular 68 (15.7) 35 (14.1) 6 (8.6) 1 (1.7) 12 (36.4) 2 (3.1) 124 (13.6)
Tubular 4 (0.9) 0 0 0 0 0 4 (0,4)
Mucinous 31 (7.2) 8 (3.2) 3 (4.3) 0 0 1 (1.6) 43 (4.7)
Papillary 19 (4.4) 7 (2.8) 3 (4.3) 1 (1.7) 0 2 (3.1) 32 (3.5)
Medullary 0 6 (2.4) 0 6 (10.0) 2 (6.1) 7 (10.9) 21 (2.3)
Metaplastic 0 1 (0.4) 0 2 (3.3) 1 (3.0) 9 (14.1) 13 (1.4)
Other 12 (2.8) 10 (4.0) 1 (1.4) 3 (5.0) 4 (12.1) 6 (9.4) 36 (4.0)
Tumour sizea (%)
\2 94 (21.7) 50 (20.1) 12 (17.1) 4 (6.7) 3 (9.1) 6 (9.4) 169 (18.6)
2–5 193 (44.6) 97 (39.0) 27 (38.6) 21 (35.0) 18 (54.5) 37 (57.8) 393 (43.2)
[5 35 (8.1) 19 (7.6) 7 (10.0) 13 (21.7) 2 (6.1) 3 (4.7) 79 (8.7)
Uncertain 111 (25.6) 83 (33.3) 24 (34.3) 22 (36.7) 10 (30.3) 18 (28.1) 268 (29.5)
Lymph node invasiona
Yes 129 (29.8) 82 (32.9) 25 (35.7) 32 (53.3) 15 (45.5) 27 (42.2) 310 (34.1)
No (C5 nodes or SNBb) 142 (32.8) 66 (26.5) 24 (34.3) 15 (25.0) 5 (15.2) 21 (32.8) 273 (30.0)
No (\5 nodes examined) 123 (28.4) 84 (33.7) 20 (28.6) 9 (15.0) 10 (30.3) 11 (17.2) 257 (28.3)
Uncertain 39 (9.0) 17 (6.8) 1 (1.4) 4 (6.7) 3 (9.1) 5 (7.8) 69 (7.6)
Stagec
I 238 (55.0) 123 (49.4) 29 (41.4) 23 (38.3) 15 (45.5) 27 (42.2) 455 (50.1)
II 157 (36.3) 90 (36.1) 28 (40.0) 27 (45.0) 14 (42.4) 30 (46.9) 346 (38.1)
III 23 (5.3) 17 (6.8) 3 (4.3) 7 (11.7) 3 (9.1) 4 (6.3) 57 (6.3)
IV 13 (3.0) 17 (6.8) 8 (11.4) 3 (5.0) 1 (3.0) 3 (4.7) 45 (5.0)
Unknown 2 (0.5) 2 (0.8) 2 (2.9) 0 0 0 6 (0.7)
a Histologically confirmed
b Sentinel node biopsy
c Cancer Registry of Norway, combined clinical and histological stage
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BP: 7.0 %. See Table 2. Mean age at diagnosis was 72.8
(SD 10.5) for women with luminal tumours and 70.9 (SD
11.8) for non-luminal tumours. Luminal A had the highest
proportion of grades 1 and 2 (Fig. 3). Only HER2 subtype
and BP comprised a higher proportion of grade 3
than grade 2. Grade 1 was not found in HER2 and 5NP
subtypes. The Luminal B subtypes had very similar
distribution of grades despite differences in other
characteristics.
Breast cancer-specific survival, molecular subtypes
and histopathological grade
Luminal A subtype had the best survival, closely followed
by Luminal B (HER2-) with 5-year BCSS higher than
75 %. The HER2 and 5NP subtypes had the poorest
prognosis, with 5-year survival around 50 %. Of the triple-
negative cases, BP had a better prognosis than 5NP. BP and
Luminal B (HER2?) were similar in terms of 5-year sur-
vival (Fig. 4).
Figure 5 shows BCSS according to histopathological
grade for up to 20 years of follow-up. Adjustment for age
did not substantially influence the curves, but after
adjustment for stage, survival for grade 1 tumours was
improved (data not shown).
Risk of death from breast cancer
Table 4 shows risk of death from breast cancer according
to molecular subtype and histopathological grade. During
the first 5 years, grades 2 and 3 had a poorer prognosis
compared to grade 1 with HR 3.8 (95 % CI 2.14–6.75) for
grade 3 and HR 1.97 (95 % CI 1.11–3.51) for grade 2. In
the same time period, the hormone receptor-negative and/
or HER2-positive subtypes had the poorest prognoses
compared to Luminal A. Particularly poor prognoses were
shown for the HER2 subtype [HR 4.24 (95 % CI
2.79–6.42)] and 5NP [HR 3.34, (95 % CI 1.91–5.82)].
After 5 years, neither grade nor molecular subtype showed
any clear association with survival. Adjustment for age had
no impact on the results, and adjustment for stage only
slightly attenuated risk estimates.
Table 5 shows risk of death from breast cancer the first
5 years after diagnosis according to molecular subtype for
grade 2 and 3. For grade 2, the HR for HER2 subtype
compared to Luminal A was 6.62 (95 % CI 2.82–15.57),
and adjustment for age and stage did not substantially
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Fig. 4 Kaplan–Meier plot. Breast cancer-specific survival according
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Table 3 The number of positive cases for each marker
Marker No. of positive (%) Not possible to interpret
ER 749 (82.4) 2 (0.2 %)
PR 521 (57.3) 1 (0.1 %)
HER2 130 (14.3) 0
Ki67 406 (44.7) 1 (0.1 %)
CK5 164 (18.0) 0
EGFR 64 (7.0) 0
0
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Pe
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Luminal A Luminal B Luminal B HER2 type 5 negative Basal
Grade 1 Grade 2 Grade 3
(HER2+)(HER2-) phenotype phenotype
Fig. 3 Distribution of grade in percent according to subtype
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influence the estimate. In grade 3, there was no clear dif-
ference in risk of death from breast cancer according to
molecular subtype. Since 12 of the 13 patients who died of
grade 1 tumours had Luminal A tumours, HRs were not
calculated. Adjustment for time period of diagnosis did not
change the results (not shown).
Amongst HER2-positive cases, the hazard ratio for the
HER2 subtype compared to Luminal B (HER2?) was 1.8
(95 % CI 1.07–3.05) (not shown in table).
Discussion
In this long-term follow-up of breast cancer patients, the
HER2 and 5NP subtypes showed the poorest prognosis
during the first 5 years after diagnosis. After 5 years, BCSS
did not significantly differ amongst the six molecular
subtypes. However, the numbers of 5-year survivors in
these two groups are low. The patients came from a cohort
of women with breast cancer who lived through a time
period with limited access to adjuvant treatment. However,
192 women would have qualified for antihormonal treat-
ment according to the treatment guidelines operative at the
time of diagnosis. None were qualified for treatment with
trastuzumab. Kaplan–Meier BCSS estimates for patients
with ER-positive tumours who may have received treat-
ment and those who did not qualify for treatment do not
differ significantly (data not shown).
During the first 5 years of follow-up, differences in
survival according to subtype occurred almost exclusively
amongst patients with grade 2 tumours. Grade 2 was sig-
nificantly associated with poorer survival for all subtypes
except Luminal B (HER2-).
These results support the findings of others that hormone
receptor status defines two groups within HER2-positive
breast cancer with differing BCSS [42]. The HER2 subtype
had the poorest 5-year survival of all subtypes, whereas the
Luminal B (HER2?) subgroup had a substantially better
Table 4 Risk of death from breast cancer according to molecular subtype and histopathological grade
No. of cases Deaths from breast cancer HR 95 % CI
unadjusted
HR 95 % CI
adjusted for age
HR 95 % CI
adjusted for stage
Histopathological grade, follow-up first 5 years after diagnosis
1 117 13 1.00 1.00 1.00
2 488 101 1.97 1.11–3.51 1.95 1.09–3.48 1.47 0.82–2.64
3 304 110 3.80 2.14–6.75 3.74 2.10–6.66 3.12 1.75–5.55
909 224
Histopathological grade, follow-up from 5 years after diagnosisa
1 78 18 1.00 1.00 1.00
2 291 83 1.37 0.82–2.29 1.29 0.77–2.16 1.21 0.72–2.02
3 153 34 0.98 0.55–1.74 0.94 0.53–1.67 0.90 0.51–1.60
522 135
Molecular subtype, follow-up first 5 years after diagnosis
Luminal A 433 73 1.00 1.00 1.00
Luminal B (HER2-) 249 56 1.42 1.01–2.02 1.42 1.00–2.02 1.29 0.92–1.84
Luminal B (HER2?) 70 25 2.33 1.48–3.67 2.36 1.48–3.74 2.11 1.33–3.33
HER2 60 32 4.24 2.79–6.42 4.39 2.86–6.72 3.72 2.44–5.65
5 Negative phenotype 33 15 3.34 1.91–5.82 3.18 1.81–5.61 3.17 1.81–5.53
Basal phenotype 64 23 2.43 1.52–3.89 2.38 1.48–3.82 2.39 1.48–3.82
909 224
Molecular subtype, follow-up from 5 years after diagnosisa
Luminal A 271 69 1.00 1.00 1.00
Luminal B (HER2-) 148 44 1.15 0.79–1.68 1.21 0.82–1.77 1.15 0.80–1.69
Luminal B (HER2?) 36 10 0.81 0.41–1.57 0.88 0.44–1.73 0.92 0.46–1.83
HER2 23 4 0.66 0.24–1.80 0.71 0.26–1.96 0.66 0.24–1.82
5 Negative phenotype 12 3 0.84 0.27–2.68 0.89 0.27–2.90 0.94 0.30–3.01
Basal phenotype 32 5 0.58 0.23–1.43 0.62 0.25–1.55 0.58 0.23–1.46
522 135
HR hazard ratio, CI confidence interval
a Conditional on surviving the first 5 years
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5-year survival, supporting the significance of ER status in
determining survival. It has been shown that, despite
problems associated with crosstalk between ER and HER2,
Luminal B (HER2?) benefits from antihormonal treatment
[20]. The hazard ratio for the HER2 subtype compared to
Luminal B (HER2?) would appear to confirm this.
To predict response to endocrine therapy, the cutoff for
ER was previously set at 10 % positive staining nuclei
[28]. In accordance with current guidelines, the cutoff is
now set at C1 % [19]. In this study, 24 cases showed ER-
positive staining in C 1 \ 10 % of tumour cell nuclei and
were classified as Luminal. A majority (16 cases) were
Luminal B, and in the Luminal B (HER2?) subtype, they
accounted for 9 % of cases. Deyarmin et al. [10] have
suggested that the classification of ER-low tumours as
Luminal may be inappropriate. These cases exert little or
no influence on the results of the Kaplan–Meier and Cox
analyses in the present study.
Classification of breast cancer into molecular subtypes
with surrogate markers for gene expression is widely used.
In 2010, Blows et al. [4] published a large collaborative
analysis that showed survival for different subtypes, where
the subtyping in all the 12 included studies was done by
IHC. These methods are more accessible and affordable
than gene profile studies and can be applied to archival
FFPE tissue. The St. Gallen Consensus Discussion in 2011
opened for molecular subtyping of breast cancer using ER,
PR, HER2 and Ki67/grade, all factors already in clinical
use, though the cutoff for Ki67 is still controversial [18].
The panel did not support the incorporation of EGFR or
CK 5/6, thus the basal phenotype and the five negative
phenotype were classified as ‘triple negative’ [15, 17].
Discussion is ongoing regarding which markers are best
suited for the classification of molecular subtypes.
In the present study, 5-year survival was better for BP
compared to 5NP. This is in contrast with the findings of
others [4, 6, 40]. The 5NP subtype had poorer prognosis
despite the fact that it comprised a higher proportion of
histological grade 2 tumours. Validation studies will reveal
whether or not this finding is consistent. This may be a
group that would have benefited from adjuvant treatment as
offered today.
Histopathological grade, tumour size and lymph node
status are strong prognostic factors and are well established
in clinical practice. Reduced long-term survival is associ-
ated with higher grade [4, 36, 44]. In the present study,
high grade was associated with non-luminal subtypes.
However, the prognostic value of the different factors may
vary with time after diagnosis [24]. Since the risk of
relapse and death is the highest during the first 5 years,
particularly for ER-negative disease [27, 41], two periods
of time were analysed separately in this study: the first
5 years after diagnosis and the subsequent years. Even after
many years, there is some risk of breast cancer recurrence.
Interestingly, in this cohort, there are no differences in
survival according to subtypes for those who have survived
the first 5 years. Further research may reveal whether
adjuvant treatment modifies this tendency.
Table 5 Risk of death from breast cancer according to molecular subtype for each histopathological grade
Number of cases Deaths from breast cancer HR 95 % CI
Unadjusted
HR 95 % CI
Adjusted for age
HR 95 % CI
Adjusted for stage
Molecular subtype, follow-up first 5 years after diagnosis: grade 2
Luminal A 297 45 1.00 1.00 1.00
Luminal B (HER2-) 120 24 1.45 0.88–2.38 1.50 0.91–2.48 1.33 0.81–2.19
Luminal B (HER2?) 33 12 2.67 1.41–5.04 2.97 1.54–5.70 2.29 1.20–4.38
HER2 10 6 6.62 2.82–15.57 7.81 3.18–19.18 5.64 2.36–13.51
5 Negative Phenotype 21 11 4.68 2.42–9.06 3.91 1.97–7.76 4.42 2.26–8.64
Basal Phenotype 7 3 3.39 1.05–10.92 2.56 0.75–8.69 3.35 1.03–10.85
488 101
Molecular subtype, follow-up first 5 years after diagnosis: grade 3
Luminal A 45 16 1.00 1.00 1.00
Luminal B (HER2–) 109 31 0.73 0.40–1.34 0.73 0.39–1.36 0.57 0.31–1.04
Luminal B (HER2?) 35 13 1.00 0.48–2.09 0.96 0.45–2.05 0.85 0.41–1.79
HER2 50 26 1.60 0.86–2.99 1.60 0.84–3.05 1.21 0.64–2.29
5 Negative Phenotype 12 4 0.90 0.30–2.70 0.87 0.28–2.64 0.94 0.31–2.82
Basal Phenotype 53 20 1.07 0.55–2.06 1.07 0.54–2.11 0.86 0.44–1.68
304 110
Follow-up first 5 years after diagnosis. HRs were not calculated for histopathological grade 1 because 12 of the 13 patients who died of grade 1
tumour had Luminal A tumour
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Histopathological grade 1 tumours are associated with
the best prognosis, whereas grade 3 tumours are associated
with the poorest prognosis. Grade 2 tumours comprise a
more heterogeneous group where the majority has an
intermediate prognosis, but some cases may exhibit simi-
larity with grades 1 and 3 [7, 32]. The same applies in this
study. It is possible to classify grade 2 tumours into low
risk and high risk of recurrence using the GGI which is
based on analysis of 97 genes [37]. A 3-gene proliferation
score using PCR assay to identify TOP2A, FOXM1 and
MKI67 has similar prognostic value as GGI and might be
easier to implement [39]. However, the present study
shows that it is possible to obtain significant additional
information of prognostic value by using already imple-
mented or readily accessible tests, and this may be of value
in prognostication of grade 2 tumours.
This study contributes to the understanding of breast cancer
heterogeneity partly because of the unique nature of the study
population. These women lived in a time before birth control
pills and hormone replacement therapy at menopause were
available, and they had not undergone organized mammog-
raphy screening. Furthermore, due to age and time period,
they had limited postoperative treatment and thus we come as
close to the natural course of the disease as possible. One
drawback in this study is the relatively high age of the cohort
and the results must be considered in light of this fact. This
may explain the relatively high proportion of grade 2 tumours
and the slightly lower proportion of HER2-positive tumours
[38]. Another weakness may be the IHC estimation of HER2
where standardized preanalytical conditions were unattain-
able, thus precluding a semiquantitative estimation of protein
expression. Despite this, there was full correlation between
IHC and CISH in 587 cases. 13 cases were IHC ? 3, but
showed chromosome 17 polysomy with ratios\2.0. Two
cases scored ?3, but no changes in chromosome or gene copy
number. For the same reason, false-positive and -negative
results may have occurred for the other biomarkers. However,
the distribution of subtypes is comparable to that of other
studies [4, 5, 9]. All laboratory tests were carried out under
standardized conditions and their interpretation together with
complete revision of the histopathological diagnoses, type and
grade was done within the context of this study according to
present-day guidelines. By adding two markers to identify the
basal phenotype to the set of markers in clinical use, it was
possible to subdivide triple-negative cases into BP and the
5NP. In this study, these two subtypes had significantly dif-
fering BCSS. Molecular tests such as GGI are promising in
terms of clinical benefit, but so far the documented benefit is
complementary to histopathological methods [32]. Similarly,
molecular subtyping using surrogate markers may provide
important additional information for selected subgroups of
breast cancer patients.
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